Rheumatic heart disease 2025 – current status and future challenges
Benjamin Jones A and David S. Celermajer B *A
B
Abstract
Rheumatic heart disease remains a major health problem for Aboriginal and Torres Strait Islander peoples. In this Reflection, potential solutions to this lamentable situation are reviewed.
Keywords: Group A Streptococcal infection, Group A Streptococcal vacine development, handheld echocardiography, rheumatic heart disease.
References
1 Australian Institute of Health and Welfare (AIHW). Acute rheumatic fever and rheumatic heart disease in Australia. 2024. Available at https://www.aihw.gov.au/reports/indigenous-australians/arf-rhd [cited 16 December 2024].
2 Bray JJH, Thompson S, Seitler S, Ali SA, Yiu J, Salehi M, Ahmad M, Pelone F, Gashau H, Shokraneh F, Ahmed N, Cassandra M, Marijon E, Celermajer DS, Providencia R. Long‐term antibiotic prophylaxis for prevention of rheumatic fever recurrence and progression to rheumatic heart disease. Cochrane Database Syst Rev [9] 2024; CD015779.
| Crossref | Google Scholar | PubMed |
3 Wyber R, Noonan K, Halkon C, Enkel S, Ralph A, Bowen A, Cannon J, Haynes E, Mitchell A, Bessarab D, Katzenellenbogen J, Seth R, Bond-Smith D, Currie B, McAullay D, D’Antoine H, Steer A, de Klerk N, Krause V, Snelling T, Trust S, Slade R, Colquhoun S, Reid C, Brown A, Carapetis J. The RHD Endgame Strategy: The blueprint to eliminate rheumatic heart disease in Australia by 2031. Perth: The END RHD Centre of Research Excellence, Telethon Kids Institute; 2020.
4 Jones B, Marangou J, Yan J, et al. NEARER SCAN (LENO BESIK) evaluation of a task-sharing echocardiographic active case finding programme for rheumatic heart disease in Australia and Timor-Leste: protocol for a hybrid type II effectiveness-implementation study. BMJ Open 2024; 14: e083467.
| Crossref | Google Scholar | PubMed |
5 Ajay Castro S, Dorfmueller HC. Update on the development of Group A Streptococcus vaccines. NPJ Vaccines 2023; 8: 135.
| Crossref | Google Scholar | PubMed |
6 Barth DD, Cinanni G, Carapetis JR, Wyber R, Causer L, Watts C, Hengel B, Matthews S, Ralph AP, Pickering J, Cannon JW, Anderson L, Wade V, Guy RJ, Bowen AC. Roadmap to incorporating group A Streptococcus molecular point-of-care testing for remote Australia: a key activity to eliminate rheumatic heart disease. Med J Aust 2022; 217(6): 279-282.
| Crossref | Google Scholar | PubMed |
7 Ralph AP, Webb R, Moreland NJ, McGregor R, Bosco A, Broadhurst D, Lassmann T, Barnett TC, Benothman R, Yan J, Remenyi B, Bennett J, Wilson N, Mayo M, Pearson G, Kollmann T, Carapetis JR. Searching for a technology-driven acute rheumatic fever test: the START study protocol. BMJ Open 2021; 11(9): e053720.
| Crossref | Google Scholar | PubMed |
8 Kado J, Salman S, Hla TK, Enkel S, Henderson R, Hand RM, Hort A, Page-Sharp M, Batty K, Moore BR, Bennett J, Anderson A, Carapetis J, Manning L. Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study. Antimicrob Agents Chemother 2023; 67(12): e0096223.
| Crossref | Google Scholar | PubMed |
9 Agenson T, Katzenellenbogen JM, Seth R, Dempsey K, Anderson M, Wade V, Bond-Smith D. Case ascertainment on Australian registers for acute rheumatic fever and rheumatic heart disease. Int J Environ Res Public Health 2020; 17(15): 5505.
| Crossref | Google Scholar | PubMed |
10 Nicholson C, Hanly M, Celermajer DS. An interactive geographic information system to inform optimal locations for healthcare services. PLOS Digit Health 2023; 2(5): e0000253.
| Crossref | Google Scholar | PubMed |
11 Marijon E, Celermajer DS, Jouven X. Rheumatic heart disease—an iceberg in tropical waters. N Engl J Med 2017; 377(8): 780-781.
| Crossref | Google Scholar | PubMed |
